Overdiagnosis is an often underappreciated harm of screening. In the context of cancer screening, it refers to the detection of cancers that appear histopathologically to be invasive malignant tumors but grow so slowly that they never would have become clinically evident during a usual lifetime or occur in a person who dies of another cause before the cancer symptoms appear.1,2 The causes of overdiagnosis include more sensitive screening tests, increasing biopsy rates, and lower thresholds for reporting abnormal-appearing cells in biopsy specimens as malignant.3-5
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ebell MH, Lin KW. Accounting for the Harms of Lung Cancer Screening. JAMA Intern Med. 2018;178(10):1422–1423. doi:10.1001/jamainternmed.2018.3061
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: